All In Biotech

Drug Trial Radar · NCT07689942

Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis

Expanded Access Program for 0.5 mg eRapa in Familial Adenomatous Polyposis

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Biodexa PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 8, 2026

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes

Summary

As written by the sponsor on the registry.

This expanded access program provides 0.5 mg eRapa (encapsulated rapamycin) to patients with familial adenomatous polyposis (FAP) who have no satisfactory alternative treatment options and are not eligible to participate in a clinical trial. The objective is to provide access to eRapa based on the treating physician's assessment that the potential benefits outweigh the potential risks, with appropriate clinical monitoring for safety and tolerability.

Conditions

  • Familial Adenomatous Polyposis (FAP)

Interventions

  • eRapa (encapsulated rapamycin)Drug

    eRapa is a proprietary oral encapsulated formulation of rapamycin (sirolimus) provided as 0.5 mg capsules. This expanded access program uses the 0.5 mg formulation specifically developed for long-term administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.